Ipamorelin vs Hexarelin
How do Ipamorelin and Hexarelin compare for Growth Hormone Axis research? Side-by-side evidence, molecular profile, EU legal status and COA-verified supplier prices — never dosing advice.
At a glance
Ipamorelin
Hexarelin
Which fits which research target?
Both Ipamorelin and Hexarelin sit within Growth Hormone Axis research but are studied for different primary signals. Neither is an approved medicine — compare the evidence, not marketing claims.
What the research shows
Ipamorelin
Hexarelin
Human studies confirm potent GH release with desensitisation upon repeated dosing — a characteristic that limits sustained use research. Cardiac research: in rat ischaemia-reperfusion models, hexarelin reduced infarct size and improved contractile function via a GH-independent mechanism (CD36 receptor). The cardioprotective profile is a distinct research angle compared to other GHRPs.
Compare prices across EU suppliers
Compare Ipamorelin across EU suppliers
16 EU vendors · COA · from €23.89
Compare Hexarelin across EU suppliers
1 EU vendors · COA · from €59
Frequently asked questions
Is Ipamorelin or Hexarelin better? ▾
Neither is an approved medicine, and “better” depends on the research target. Ipamorelin is most associated with GH pulse stimulation, while Hexarelin is studied for Growth Hormone Axis. Compare the evidence tiers and COA-verified EU pricing above rather than assuming one is superior. This is not a usage recommendation.
Why compare Ipamorelin and Hexarelin? ▾
Both are studied within Growth Hormone Axis research through different mechanisms, so researchers often weigh them against each other. This page sets their evidence, molecular profile, EU legal status and supplier pricing side by side.
Which is cheaper in the EU, Ipamorelin or Hexarelin? ▾
Prices vary by supplier, vial size and COA status. Ipamorelin is listed from €23.89 across 16 COA-verified EU vendors; Hexarelin from €59 across 1. Open the price pages above to compare current listings — nobody pays us for placement.